Topic Hub
17 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 17 of 17 clinical reviews.
A clinical evidence summary of retatrutide's off-label use in heart failure, covering GIP/GLP-1/glucagon receptor pharmacology, available trial data, GRADE-level evidence, and what physicians need to know before considering it.
Read clinical reviewRetatrutide is not FDA-approved for heart failure, but early trial data on weight loss and cardiometabolic markers suggest potential benefit. Here is what clinicians and patients should know about off-label use, dosing, and the current evidence base.
Read clinical reviewRetatrutide is an investigational triple-agonist peptide not approved for heart failure. Learn what early data suggest, how clinicians monitor off-label use, and what trials to watch.
Read clinical reviewRetatrutide is an investigational triple-agonist not approved for any indication. Here is what clinicians should know about its potential off-label use in heart failure, including evidence gaps, mechanistic promise, and safety concerns.
Read clinical reviewRetatrutide is not FDA-approved for NASH. Learn what the phase 2 trial data actually show, how the triple-agonist mechanism maps to NASH biology, and what clinicians and patients need to weigh before considering off-label use.
Read clinical reviewA clinical evidence summary of retatrutide's off-label use for nonalcoholic steatohepatitis (NASH), including trial data, mechanism, dosing considerations, and physician guidance.
Read clinical reviewRetatrutide is not FDA-approved for NASH, but early phase 2 data show meaningful liver fat reduction. Learn what the evidence says, who may be a candidate, and what monitoring your clinician should order.
Read clinical reviewRetatrutide is not FDA-approved for PCOS, but its triple-agonist mechanism addresses insulin resistance, hyperandrogenism, and weight, the three core drivers of polycystic ovary syndrome. Learn what the phase 2 data show, how clinicians are dosing it off-label, and what risks to weigh.
Read clinical reviewRetatrutide is not FDA-approved for PCOS, but early trial data suggest it may improve metabolic and hormonal markers. Learn what the evidence shows, what monitoring is required, and how to discuss this option with your clinician.
Read clinical reviewRetatrutide is not FDA-approved for PCOS. This guide covers the off-label case for using this triple GIP/GLP-1/glucagon agonist in PCOS, the current evidence level, real risks, and how it compares to approved options.
Read clinical reviewIs retatrutide a viable off-label option for obstructive sleep apnea? We review the phase 2 trial data, proposed dosing protocols, FDA status, and what clinicians need to know before prescribing.
Read clinical reviewWhat does the clinical evidence say about using retatrutide off-label for obstructive sleep apnea? We review trial data, weight-loss outcomes, AHI reductions, and how this triple-agonist compares to approved therapies.
Read clinical reviewRetatrutide is not FDA-approved for sleep apnea. This HealthRX review covers the current off-label evidence, mechanism, GRADE-level certainty, real trial data, risks, and how to talk to your prescriber.
Read clinical reviewRetatrutide is not yet FDA-approved for any indication. Learn what Phase 2 trial data show about its weight-loss potential, how it compares to semaglutide and tirzepatide, and what monitoring protocols apply to off-label use.
Read clinical reviewRetatrutide is a triple-hormone receptor agonist showing up to 24.2% body weight reduction in Phase 2 trials. Learn about off-label dosing protocols, safety data, and how it compares to approved GLP-1 therapies.
Read clinical reviewA clinical evidence summary of retatrutide for weight loss, including phase 2 trial data, mechanism of action, dosing, safety profile, and current regulatory status of this investigational triple-receptor agonist.
Read clinical reviewRetatrutide is an investigational triple-agonist showing up to 24% body weight reduction in Phase 2 trials. Learn about off-label use, safety data, and how it compares to approved GLP-1 options.
Read clinical review